Well it seems perhaps I was mistaken in thinking this was the data from the 2015 phase 2 trial SI waws referring to. The announcement does reference the DreamHF trial and says it is "new data". So my apologies if I caused confusion
Even so, it does raise a lot of questions as to why it was released this way?
Why did SI present it at an online presentation before making a formal announcement to the market without any trading halt?
Where is Dr Perin, the chief investigator in all of this?
Why is the announcement so short on context and other relevant information?
Something doesn't seem right.
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE, page-138
-
- There are more pages in this discussion • 162 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.01 |
Change
-0.010(0.98%) |
Mkt cap ! $1.153B | |||
| Open | High | Low | Value | Volume |
| $1.02 | $1.04 | $1.01 | $2.272M | 2.225M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 10528 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.02 | 182880 | 31 |
View Market Depth
| Last trade - 14.40pm 01/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |